Percutaneous ablation of painful metastases involving bone

Matthew R Callstrom, J. William Charboneau

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Skeletal metastases are commonly encountered in cancer patients and often result in great pain and morbidity (1). Autopsy studies have shown that in patients who die from breast, prostate and lung cancer, up to 85% have evidence of bone metastasis at the time of death (2). Severe pain and frequent fractures resulting from metastatic cancer reduce the patients' quality of life and often lead to depression and mood changes. The current standard of care for cancer patients with localized bone pain is external beam radiation therapy (RT). While most patients experience a reduction of pain, 20% to 30% of patients do not have relief. A recent review of 1, 016 patients treated by RT demonstrated complete relief in 53% and partial relief in 83% (3). Additionally, following treatment, there is usually a delay of 4 to 12 weeks before pain relief is achieved, and many patients will experience a return of significant pain within a few months (3). Other conventional therapies have specific, although limited, usefulness for treating painful metastatic disease. Surgery is usually reserved for fixation of a recent or impending fracture. Chemotherapy is usually ineffective for reduction of bone pain, although bisphosphonate therapy is useful for metastatic breast and prostate cancers (4–7). Radiopharmaceuticals may be of value for treatment of some patients with diffuse bone metastases but is not used for patients with focal painful metastatic disease (8–10).

Original languageEnglish (US)
Title of host publicationInterventional Oncology: Principles and Practice
PublisherCambridge University Press
Pages498-510
Number of pages13
ISBN (Print)9780511722226, 9780521864138
DOIs
StatePublished - Jan 1 2008

Fingerprint

Neoplasm Metastasis
Bone and Bones
Pain
Prostatic Neoplasms
Radiotherapy
Breast Neoplasms
Neoplasms
Radiopharmaceuticals
Diphosphonates
Therapeutics
Standard of Care
Autopsy
Lung Neoplasms
Quality of Life
Depression
Morbidity
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Callstrom, M. R., & William Charboneau, J. (2008). Percutaneous ablation of painful metastases involving bone. In Interventional Oncology: Principles and Practice (pp. 498-510). Cambridge University Press. https://doi.org/10.1017/CBO9780511722226.040

Percutaneous ablation of painful metastases involving bone. / Callstrom, Matthew R; William Charboneau, J.

Interventional Oncology: Principles and Practice. Cambridge University Press, 2008. p. 498-510.

Research output: Chapter in Book/Report/Conference proceedingChapter

Callstrom, MR & William Charboneau, J 2008, Percutaneous ablation of painful metastases involving bone. in Interventional Oncology: Principles and Practice. Cambridge University Press, pp. 498-510. https://doi.org/10.1017/CBO9780511722226.040
Callstrom MR, William Charboneau J. Percutaneous ablation of painful metastases involving bone. In Interventional Oncology: Principles and Practice. Cambridge University Press. 2008. p. 498-510 https://doi.org/10.1017/CBO9780511722226.040
Callstrom, Matthew R ; William Charboneau, J. / Percutaneous ablation of painful metastases involving bone. Interventional Oncology: Principles and Practice. Cambridge University Press, 2008. pp. 498-510
@inbook{0dfe7bddcc9b4633b929f266d73db4a1,
title = "Percutaneous ablation of painful metastases involving bone",
abstract = "Skeletal metastases are commonly encountered in cancer patients and often result in great pain and morbidity (1). Autopsy studies have shown that in patients who die from breast, prostate and lung cancer, up to 85{\%} have evidence of bone metastasis at the time of death (2). Severe pain and frequent fractures resulting from metastatic cancer reduce the patients' quality of life and often lead to depression and mood changes. The current standard of care for cancer patients with localized bone pain is external beam radiation therapy (RT). While most patients experience a reduction of pain, 20{\%} to 30{\%} of patients do not have relief. A recent review of 1, 016 patients treated by RT demonstrated complete relief in 53{\%} and partial relief in 83{\%} (3). Additionally, following treatment, there is usually a delay of 4 to 12 weeks before pain relief is achieved, and many patients will experience a return of significant pain within a few months (3). Other conventional therapies have specific, although limited, usefulness for treating painful metastatic disease. Surgery is usually reserved for fixation of a recent or impending fracture. Chemotherapy is usually ineffective for reduction of bone pain, although bisphosphonate therapy is useful for metastatic breast and prostate cancers (4–7). Radiopharmaceuticals may be of value for treatment of some patients with diffuse bone metastases but is not used for patients with focal painful metastatic disease (8–10).",
author = "Callstrom, {Matthew R} and {William Charboneau}, J.",
year = "2008",
month = "1",
day = "1",
doi = "10.1017/CBO9780511722226.040",
language = "English (US)",
isbn = "9780511722226",
pages = "498--510",
booktitle = "Interventional Oncology: Principles and Practice",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Percutaneous ablation of painful metastases involving bone

AU - Callstrom, Matthew R

AU - William Charboneau, J.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Skeletal metastases are commonly encountered in cancer patients and often result in great pain and morbidity (1). Autopsy studies have shown that in patients who die from breast, prostate and lung cancer, up to 85% have evidence of bone metastasis at the time of death (2). Severe pain and frequent fractures resulting from metastatic cancer reduce the patients' quality of life and often lead to depression and mood changes. The current standard of care for cancer patients with localized bone pain is external beam radiation therapy (RT). While most patients experience a reduction of pain, 20% to 30% of patients do not have relief. A recent review of 1, 016 patients treated by RT demonstrated complete relief in 53% and partial relief in 83% (3). Additionally, following treatment, there is usually a delay of 4 to 12 weeks before pain relief is achieved, and many patients will experience a return of significant pain within a few months (3). Other conventional therapies have specific, although limited, usefulness for treating painful metastatic disease. Surgery is usually reserved for fixation of a recent or impending fracture. Chemotherapy is usually ineffective for reduction of bone pain, although bisphosphonate therapy is useful for metastatic breast and prostate cancers (4–7). Radiopharmaceuticals may be of value for treatment of some patients with diffuse bone metastases but is not used for patients with focal painful metastatic disease (8–10).

AB - Skeletal metastases are commonly encountered in cancer patients and often result in great pain and morbidity (1). Autopsy studies have shown that in patients who die from breast, prostate and lung cancer, up to 85% have evidence of bone metastasis at the time of death (2). Severe pain and frequent fractures resulting from metastatic cancer reduce the patients' quality of life and often lead to depression and mood changes. The current standard of care for cancer patients with localized bone pain is external beam radiation therapy (RT). While most patients experience a reduction of pain, 20% to 30% of patients do not have relief. A recent review of 1, 016 patients treated by RT demonstrated complete relief in 53% and partial relief in 83% (3). Additionally, following treatment, there is usually a delay of 4 to 12 weeks before pain relief is achieved, and many patients will experience a return of significant pain within a few months (3). Other conventional therapies have specific, although limited, usefulness for treating painful metastatic disease. Surgery is usually reserved for fixation of a recent or impending fracture. Chemotherapy is usually ineffective for reduction of bone pain, although bisphosphonate therapy is useful for metastatic breast and prostate cancers (4–7). Radiopharmaceuticals may be of value for treatment of some patients with diffuse bone metastases but is not used for patients with focal painful metastatic disease (8–10).

UR - http://www.scopus.com/inward/record.url?scp=84932601690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932601690&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511722226.040

DO - 10.1017/CBO9780511722226.040

M3 - Chapter

AN - SCOPUS:84932601690

SN - 9780511722226

SN - 9780521864138

SP - 498

EP - 510

BT - Interventional Oncology: Principles and Practice

PB - Cambridge University Press

ER -